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following inoculation with brain extract containing in vivo-
generated PrP amyloid fibrils, which has not been shown 
for other synthetic prion models. These data are reminis-
cent of the “prion-like” spread of aggregated forms of the 
beta-amyloid peptide (Aβ), α-synuclein and tau observed 
following inoculation of transgenic mice with pre-formed 
seeds of each misfolded protein. Hence, even when the 
protein is PrP, misfolding and aggregation do not repro-
duce the full clinicopathological phenotype of disease. The 
initiation and spread of protein aggregation in transgenic 
mouse lines following inoculation with pre-formed fibrils 
may, therefore, more closely resemble a seeded proteinopa-
thy than an infectious TSE disease.
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Introduction
The misfolding and aggregation of host protein in the brain 
is a pathological characteristic of several neurodegenerative 
diseases, such as Alzheimer’s disease (AD), Parkinson’s 
disease (PD) and transmissible spongiform encephalopa-
thy (TSE). However, the actual role of these protein aggre-
gates in the neurodegenerative process is currently unclear. 
TSEs differ from other neurodegenerative diseases, since 
they affect several mammalian species other than humans 
and are infectious. TSEs such as scrapie in sheep and goats, 
bovine spongiform encephalopathy (BSE) in cattle and 
Creutzfeldt–Jakob disease (CJD) in humans can be trans-
mitted between individuals of the same species and, in 
some cases, can spread between different species. TSEs 
exist as a large number of strains/isolates that show spe-
cific, reproducible clinical and pathological characteristics 
on transmission in animals. They can be contagious and 
Abstract Mammalian prions are unusual infectious agents, 
as they are thought to consist solely of aggregates of mis-
folded prion protein (PrP). Generation of synthetic prions, 
composed of recombinant PrP (recPrP) refolded into fibrils, 
has been utilised to address whether PrP aggregates are, 
indeed, infectious prions. In several reports, neurological 
disease similar to transmissible spongiform encephalopa-
thy (TSE) has been described following inoculation and 
passage of various forms of fibrils in transgenic mice and 
hamsters. However, in studies described here, we show that 
inoculation of recPrP fibrils does not cause TSE disease, 
but, instead, seeds the formation of PrP amyloid plaques in 
PrP-P101L knock-in transgenic mice (101LL). Importantly, 
both WT-recPrP fibrils and 101L-recPrP fibrils can seed 
plaque formation, indicating that the fibrillar conforma-
tion, and not the primary sequence of PrP in the inoculum, 
is important in initiating seeding. No replication of infec-
tious prions or TSE disease was observed following both 
primary inoculation and subsequent subpassage. These 
data, therefore, argue against recPrP fibrils being infectious 
prions and, instead, indicate that these pre-formed seeds are 
acting to accelerate the formation of PrP amyloid plaques 
in 101LL Tg mice. In addition, these data reproduce a 
phenotype which was previously observed in 101LL mice 
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can spread horizontally between animals in the field, such 
as scrapie in sheep and chronic wasting disease (CWD) 
in deer [60]. Other TSEs, such as BSE in cattle and CJD 
in humans, are not contagious, but are infectious, and can 
be transmitted indirectly between individuals following 
ingestion of contaminated tissues [3, 4, 19, 73], inocula-
tion of such tissues into the CNS or periphery [1, 2, 7, 36], 
or transfusion of blood [26, 27, 38, 57, 74]. The infectious 
agent responsible for TSE is not a conventional patho-
gen such as a bacterium or virus. However, the disease is 
caused by a titratable infectious agent, which maintains 
specific characteristics on transmission in animals. It is 
thought that the infectious agent is a misfolded form of the 
host prion protein (PrPC) [59]. This misfolded protein prop-
agates by binding to and converting PrPC into the abnormal 
isoform (PrPSc), and this autocatalytic conversion results 
in the deposition and spread of PrPSc through the central 
and peripheral nervous system, and also some viscera such 
as the lymphoreticular system, in patterns characteristic of 
each individual TSE strain/isolate.
The central role of the prion protein in TSE disease has 
led to the infectious agent being termed a prion [59] and 
the disease being referred to as prion disease. However, the 
term “prion” or “prion-like” has more recently been used 
to describe the observed spread of protein aggregates and 
amyloid accumulation in the brains of transgenic mice 
expressing either wild-type or mutant [51] human amy-
loid precursor protein (APP), following intracerebral [47, 
49, 70, 71] and peripheral [17] inoculation with pre-formed 
aggregates of beta-amyloid peptide (Aβ). Similar models of 
induced protein aggregation have also been described for 
PD (inoculation of α-synuclein aggregates) [50], amyo-
trophic lateral sclerosis (ALS) (inoculation of misfolded 
SOD-1) [52] and tauopathy (inoculation of filamentous 
tau) [11]. “Prion-like” spread occurs when pre-formed 
protein aggregates are introduced into a host, which has 
the effect of accelerating the misfolding and aggregation 
of the endogenous host protein in the brain. On this basis, 
it is entirely possible that these pre-formed aggregates of 
Aβ, α-synuclein, SOD-1 and tau are acting as “prions” and 
are providing a template driving the misfolding of normal 
cellular forms of the protein into amyloid fibrils. However, 
in APP transgenic mouse models, acceleration of protein 
aggregation has been observed only following direct intrac-
erebral inoculation [47, 50, 71] or peripheral inoculation 
[17]. Protein aggregation is not accelerated by oral, intra-
venous, intraocular or intranasal inoculation [15]. Several 
groups have demonstrated the potential for existence of 
“strains” of Aβ and α-synuclein [5, 25], and other reports 
described Aβ amyloid plaques in human growth hormone 
recipients [28, 29], and dura matter graft recipients [21, 
35]. However, no definitive evidence of direct or indirect 
transmission has been described for either AD or PD in 
humans [28].
The generic use of the terms “prion” and “prion-like” 
to describe various aspects of all neurodegenerative dis-
eases does, therefore, cause confusion. AD, PD, ALS and 
tauopathy are not transmissible diseases, and there is no 
epidemiological evidence to support an infectious aetiol-
ogy [28]. These diseases are, therefore, distinctly different 
in their aetiology from TSEs. It has been proposed that the 
extended term “propagon” could be used to simply describe 
that a misfolded protein is being propagated, and avoid 
confusion over prion transmissibility and infection [16]. In 
this paper, we will use the terms “prion” and “prion-like” to 
describe the general mechanism of protein aggregation and 
spread, and not as a surrogate for TSE.
Although the TSE agent is thought to be PrPSc, previ-
ous work from our laboratory has shown that PrP aggre-
gation does not always lead to replication of an infectious 
agent and subsequent TSE [55, 56]. There exists a subset of 
cases in which PrP aggregates are formed in the brain in the 
absence of TSE agent replication [9, 10, 24, 55, 56]. One 
such disorder that exemplifies this phenomenon is a vari-
ant of Gerstmann–Sträussler–Scheinker (GSS) disease, a 
familial human TSE disease characterised by PrP amyloid 
plaque deposition. The most common form of GSS is asso-
ciated with a proline-to-leucine mutation at PrP codon 102 
(GSS P102L) [54]. Inoculation of knock-in transgenic mice 
homozygous for the equivalent mutation in murine PrP 
(101LL) with classical forms of GSS P102L (associated 
with spongiform degeneration and diffuse PrP deposition) 
resulted in the development of clinical and pathological 
signs of TSE disease. When 101LL mice were inoculated 
with atypical forms of GSS P102L (no spongiform change 
and PrP amyloid plaques), inefficient disease transmission 
was observed with most animals surviving for full lifespan 
with no clinical signs or spongiform degeneration. How-
ever, on postmortem analysis, many of the inoculated mice 
were found to have large PrP amyloid plaques in the brain 
[56]. Similarly, when 101LL mice were inoculated with 
brain homogenate from sick GSS22 mice [53] (which over-
express 101L murine PrP and spontaneously develop neu-
rological signs and large PrP amyloid plaques), no clinical 
signs of TSE disease or spongiform degeneration were evi-
dent, but large PrP amyloid plaques were again identified in 
the brains of these mice postmortem [55]. Hence, extracts 
from both humans with an atypical form of GSS P102L 
and transgenic mice (GSS22) overexpressing murine 101L-
PrP (both characterised by PrP amyloid plaque disposi-
tion) do not transmit TSE disease to 101LL mice. Compo-
nents of the brain inoculum are instead capable of seeding 
the aggregation of PrP amyloid plaques in recipient mice 
expressing 101L but not wild-type PrP. However, disease 
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may be transmissible from such atypical TSE isolates in 
other model systems [58].
Although the above data argue for a direct “seeding” 
of PrP amyloid deposition by pre-formed PrP aggregates 
in the inoculum, our experiments performed to date have 
utilised brain material harvested from individual patients 
or mice with neurological symptoms, which may contain 
other components, or possibly low levels of an infectious 
agent, in addition to pre-formed PrP amyloid seeds. There-
fore, in this study, we aimed to investigate directly whether 
misfolded forms of PrP, in the absence of other components 
of brain homogenate, can seed amyloid plaque formation, 
or cause TSE disease, following intracerebral inoculation in 
recipient mice. To this end, wild-type murine recombinant 
PrP (WT-recPrP) and 101L murine recPrP (101L-recPrP) 
preparations were refolded into different conformations 
in vitro and inoculated into groups of wild-type 129/Ola 
and 101LL mice to examine the ability of the different 
recombinant PrP (recPrP) conformers to either seed PrP 
amyloid plaques, or cause the development of TSE disease 
in 101LL mice. In contrast to other studies describing inoc-
ulation of recPrP fibrils [12, 13, 37, 39, 40, 42, 43, 61, 66], 
we saw no TSE disease in recipient mice, but did reproduce 
the seeding of PrP amyloid plaques observed in our previ-
ous work following inoculation of brain extract containing 
in vivo-derived amyloid fibrils.
Materials and methods
Transgenic mice
101LL knock-in transgenic mice express the murine PrP 
gene containing a proline-to-leucine mutation at codon 101. 
The mice were produced by homologous recombination in 
embryonic stem cells and have been described previously 
[44, 48]. 101LL mice are maintained on the same genetic 
background as control wild-type 129/Ola mice, allowing 
direct comparison of results between wild-type and mutant 
mice, without the complication of transgene overexpres-
sion, or other effects caused by random integration of the 
transgene in the murine genome.
Production and refolding of recPrP isoforms
Cloning and expression of wild-type, murine recPrP has 
previously been described in detail [33]. An equivalent 
expression plasmid was created in which the proline at 
codon 101 was changed to leucine, and both forms of the 
protein were expressed in Rosetta Escherichia coli bacteria. 
For refolding into monomeric or oligomeric forms, proteins 
were purified by sequential Ni-IMAC and ion-exchange 
chromatographies, and the single disulphide bond made by 
overnight oxidation catalysed by copper ions, as previously 
published [63]. Copper ions and denaturant were removed 
by dialysis into 50 mM sodium acetate, pH 5.5, and the 
final protein snap-frozen prior to use. For refolding into 
fibrillar isoforms, recPrP was purified by sequential Ni-
IMAC and gel filtration after which the single disulphide 
bond was created using glutathione shuffling; the protein 
was, then, further purified by reverse-phase HPLC, as per 
previous reports [23]. Final elution fractions were lyoph-
ilised and snap-frozen prior to use. To control for environ-
mental contamination, a saline eluate from the final column 
was also prepared, which was subjected to the same refold-
ing conditions detailed for each different PrP isoform. This 
preparation was inoculated into groups of mice to control 
for possible TSE contamination.
RecPrP in 50 mM sodium acetate, pH 5.5, was shown 
to possess an α-helical conformation by far-UV circular 
dichroism (CD) spectroscopy, which produced the expected 
double minima at 210 and 222 nm. Prior to inoculation, 
samples were spun briefly to remove aggregates, and 
passed through a 0.22-µm filter to sterilise. Protein assays 
indicated concentrations of 1.33 mg/ml for 101L-recPrP, 
and 0.48 mg/ml for WT-recPrP.
Oligomer formation followed a procedure originally 
developed by Rezaei et al. [62]. Oligomerisation of recPrP 
was initiated by buffer exchange of samples at ~2 mg/ml 
into 50 mM sodium citrate (pH 3.4) [32]. The samples were 
heated overnight, and an increase in oligomeric PrP forms 
was confirmed by size exclusion chromatography using a 
TSKgel G3000SW (Tosoh). Prior to inoculation, samples 
were spun briefly to remove any larger aggregates that may 
have formed during storage, and passed through a 0.22-µm 
filter to sterilise. Protein assays were performed to confirm 
that protein was recovered following centrifugation and fil-
tration. Concentrations of 0.33 mg/ml for 101L-recPrP, and 
0.44 mg/ml for WT-recPrP were obtained.
RecPrP stocks were fibrillised into amyloid by incuba-
tion under moderately denaturing conditions with vigor-
ous shaking [23]. Conversion to amyloid was monitored by 
thioflavin T fluorescence. The presence of fibrils was con-
firmed by demonstrating that a 16-kDa band was retained 
following digestion with proteinase K [6]. Fibrillar mor-
phology of the refolded recPrP fibrils (70 μg/ml diluted in 
10 mM NaAc buffer) was confirmed by phosphotungstic 
acid negative staining technique and electron microscopy. 
Formvar-coated copper grids were placed onto a 50-μl 
drop of fibril preparation. After 45 s, the grid was removed, 
touched to a filter paper to remove excess fluid and, then, 
placed onto a drop of filtered 2 % aqueous phosphotung-
stic acid for 2 min. Grids were then air-dried before storage 
and examined using a Jeol 1200EX transmission electron 
microscope. Since fibrillar PrP samples were composed 
of large aggregates, no filter sterilisation was performed 
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on these inocula. Instead, samples of inocula were plated 
on blood agar and incubated both aerobically and anaero-
bically to confirm lack of bacterial contamination prior to 
inoculation. Protein concentrations for amyloid prepara-
tions were 0.07 mg/ml for the 101L-recPrP and 0.40 mg/ml 
for the WT-recPrP.
Inoculation of transgenic mice
Stocks of each 101L-recPrP and WT-recPrP preparation 
(monomers, oligomers and fibrils) were diluted to 100 µg/
ml (α-monomeric), 150 µg/ml (oligomers) and 70 µg/
ml (fibrils) for inoculation. Oligomeric preparations con-
tain a small proportion of α-monomeric material (~1:3 
ratio monomers:oligomers) and were, therefore, diluted to 
150 µg/ml to allow inoculation of equivalent amounts of 
oligomers to the pure monomer preparations. To control for 
possible TSE contamination during preparation and refold-
ing, three control buffer eluates from the chromatographic 
separations were processed through the refolding/misfold-
ing steps required to produce monomers, oligomers and 
fibrils, and inoculated as contamination controls (mono-
mer control, oligomer control and amyloid fibril control). 
Nine groups of 48 mice (24 × 101LL and 24 × wild type 
mice aged approximately 4–10 weeks) were anaesthetised, 
and each group inoculated with 20 μl of a single recPrP or 
control preparation. Inoculations were performed manually 
with a 26-gauge needle into the right cerebral hemisphere 
(to the right of the midline and centrally between the eye 
and the ear). Needle guards were used to ensure a consist-
ent depth of penetration (~2 mm). Mice were monitored 
through recovery from the anaesthetic, and transferred to 
new cages with fresh bedding, food and water.
For subpassage experiments, 10 % brain homogen-
ates were prepared from the contralateral (non-inoculated) 
left cerebral hemisphere samples from selected animals 
that received either recPrP or control inocula as described 
above. Tissues were selected from two 101LL mice that 
received 101L-recPrP oligomers, two 101LL mice that 
received 101L-recPrP or WT-recPrP amyloid fibrils, one 
101LL mouse that received control oligomer inoculum, and 
one 101LL mouse that received control amyloid fibril inoc-
ulum. The six inocula were injected intracerebrally (20 µl) 
into groups of 48 mice (24 × 101LL mice and 24 × wild-
type mice at ~4–10 weeks of age) as described above.
At 150 days post-inoculation, a formal clinical monitor-
ing system was started. Animals were scored weekly for 
clinical signs, indicative of TSE disease, by trained observ-
ers according to a previously established TSE clinical scor-
ing system [14]. Observers were also requested to note 
any other unusual behaviour or neurological signs in these 
animals. The characteristic signs of clinical TSE infec-
tion may include; lethargy, hyperactivity, ataxia, pruritis, 
gait effect, and aggression depending on the combination 
of TSE and mouse strain. Non-specific signs in the animal 
may be observed for a few weeks prior to the development 
of definite neurological signs which normally occur during 
the last 2–3 weeks of the incubation period. Animals were 
scored as 1 (Normal); 2 (possibly affected—evidence of 
some signs but not necessarily related to TSE); +(definitely 
affected. Animal shows clinical signs of TSE); g (animal 
has gait abnormality but not clinical TSE); G (animal has 
clinical TSE score and gait abnormality). Animals were 
culled by a schedule 1 method after (a) two consecutive 
weekly scores of “definitely affected” (+ or G) or (b) after 
receiving scores of “definitely affected” (+ or G) in two out 
of three consecutive weeks, or (c) for welfare reasons after 
consultation with the NACWO. Achieving two “definitely 
affected” scores increases the confidence that the clinical 
diagnosis of TSE is correct.
Half the brain was snap-frozen in liquid nitrogen for 
biochemical analysis or passage (contralateral to injection 
site), and the remaining half brain (ipsilateral to injection 
site) was fixed in formol saline and paraffin-embedded for 
histological processing. When tissue showed autolysis, 
whole brain was processed for histology. All mouse experi-
ments were approved by the Local Ethical Review com-
mittee and performed under Licence from the UK Home 
Office in accordance with the Animals (Scientific Proce-
dures) Act 1986.
Vacuolation scoring
Sections (6 µm) were cut from paraffin-embedded mouse 
brain tissue and stained using haematoxylin and eosin 
(H&E). Spongiform degeneration was assessed at nine 
grey-matter regions (medulla, cerebellum, superior col-
liculus, hypothalamus, thalamus, hippocampus, septum, 
retrospinal cortex, cingulated and motor cortex) and three 
regions of white matter (cerebellar white matter, mid-
brain white matter, and cerebral peduncle). Sections were 
scored on a scale of 0 (absence) to 5 (severe) for the pres-
ence and severity of spongiform degeneration as previously 
described [8, 20].
Immunohistochemistry of formol saline 
immersion‑fixed tissue (light microscopy analysis)
Sections (6 µm) were cut from paraffin-embedded mouse 
brain tissue, autoclaved for 15 min at 121 °C and immersed 
in 95 % (v/v) formic acid for 10 min prior to overnight incu-
bation with 0.44 g/ml anti-PrP monoclonal antibody (MAb) 
6H4 (Prionics) at room temperature. Secondary anti-mouse 
biotinylated antibody (Jackson Immuno Research Labora-
tories, UK) was added at 2.5 g/ml and incubated for 1 h at 
room temperature. Immunolabelling was performed using 
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the ABC Elite kit (Vector Laboratories), and the signal was 
visualised by a reaction with hydrogen peroxidase-acti-
vated diaminobenzidine. Sections were blinded and exam-
ined for PrP deposition without knowledge of genotype or 
inoculum.
Immunohistochemistry of paraformaldehyde/
glutaraldehyde perfusion‑fixed tissue (light and electron 
microscopic analysis)
Brain tissue from two 101LL mice inoculated with 101L 
amyloid fibrils, two 101LL mice inoculated with wild-type 
amyloid fibrils, and two wild-type mice inoculated with 
101L amyloid fibrils were perfusion-fixed in 4 % paraform-
aldehyde/0.1 % glutaraldehyde at cull >600 days follow-
ing intracerebral challenge. Alternate fixed serial coronal 
brain slices (1 mm) were embedded in paraffin wax or were 
further trimmed into 1-mm3 blocks, post fixed in osmium 
tetroxide and embedded in araldite resin.
Light microscopy (wax)
Wax-embedded blocks were cut and stained with H&E or 
were labelled using a light microscopic immunohistochem-
ical procedure as described previously [22]. PrP MAbs 
SAF84 (Bertin Pharma, Montigny le Bretonneux, France) 
and 1C5 (Y.S. Kim, Hallym University, Republic of 
Korea), and polyclonal antibodies 1A8 [18] and R523.7 (J. 
Langeveld, ID–Lelystad, Netherlands) were applied over-
night at 27 °C, at dilutions of 1:2000, 1: 1000, 1:1000 and 
1:12,000, respectively. Polyclonal anti-glial fibrillary acidic 
protein (GFAP) and anti-ubiquitin antibodies (both Dako, 
Ely, Cambridgeshire, UK) were also applied at dilutions of 
1:8000 or 1:500 (respectively).
Light microscopy (resin )
As described previously [46], the avidin–biotin complex 
immunohistochemical staining method was applied to the 
etched and pre-treated sections using SAF84 at a dilution 
of 1:400 and 1A8 at a dilution of 1:2000. Mice infected 
with 87 V mouse scrapie were used as positive controls due 
to the PrP amyloid plaque pathology.
Ultrastructural microscopy
At least three blocks of corpus callosum or hippocampus 
containing immunolabelled plaques were identified in 
each of the two 101LL mice inoculated with 101L-recPrP 
amyloid fibrils. Blocks containing corpus callosum and 
hippocampus were also taken for analysis from both 87 V 
controls and from the wild-type mouse inoculated with 
101L-recPrP amyloid fibrils. Multiple sections (65 nm) 
from each block were stained using uranyl acetate and 
lead citrate, or immunolabelled using 1A8 as described 
previously [46]. A pre-immune serum was applied to each 
section as a control. Grids were examined using a Jeol 
1200EX transmission electron microscope.
Detection of amyloid plaques by thioflavin‑S 
fluorescence
Amyloid deposits in tissue sections were observed using 
thioflavin-S. Briefly, following haematoxylin staining, 
sections (6 µm) were immersed in 1 % (w/v) thioflavin-S 
(Sigma, UK) solution as previously described [54]. Sec-
tions were mounted and viewed under a fluorescence 
microscope.
Detection of PK‑resistant PrP by histoblotting
Sections (6 µm) were cut from paraffin blocks onto strips 
of nitrocellulose membrane. These were processed as 
described previously [65], and digested with PK (20 µg/ml) 
overnight at 55 °C. Blots were probed with anti-PrP Mab 
BH1 (1/3000) [45] and plaques visualised with goat anti-
mouse alkaline phosphatase secondary (1/5000) and NBT/
BCIP tablets (Sigma).
PCR genotyping of mouse tail DNA
All mice were analysed by PCR postmortem to confirm 
PrP genotype. Mouse tail DNA was extracted and genotype 
verified by PCR as previously described [44].
Results
Inoculation of α‑monomeric, oligomeric and fibrillar 
recPrP preparations does not induce TSE disease 
in mice
Purified PrP fibrils were produced from recPrP to examine 
whether PrP aggregates alone could seed PrP amyloid for-
mation or induce TSE disease in 101LL mice. WT-recPrP 
and 101L-recPrP proteins were expressed, purified and 
refolded into a native-like α-helical, monomeric isoform, as 
well as isoforms possessing oligomeric and amyloid fibril-
lar morphologies. Tertiary/quaternary structures of the pro-
teins were confirmed by far-UV circular dichroism (CD) 
spectroscopy and size exclusion chromatography for mono-
mers and oligomers. Fibril preparations were analysed by 
both limited protease digestion and electron microscopy 
to confirm fibrillar structure (Fig. 1). Each refolded recPrP 
preparation, plus control eluates from the chromatographic 
purification steps (9 inocula in total), were inoculated into 
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groups of 24 101LL and 24 wild-type mice (Table 1). 
Experiments were terminated at approximately 700 days 
post-inoculation. Of the 432 mice inoculated, 54 mice died 
due to intercurrent illness with no tissue harvested. The 
remaining 378 animals were culled for welfare reasons 
(between 126 and 702 days post-inoculation), except for 
three 101LL mice (one each inoculated with WT-recPrP 
oligomer, 101L-recPrP oligomer and oligomer saline con-
trol) that were culled showing possible clinical signs of 
TSE disease (605, 619 and 637 days old). No other adverse 
behavioural or neurological phenotypes were observed in 
any of the mice. Brain tissue was removed from all 378 
mice and subjected to histopathological analysis for TSE 
disease pathology. None of the 378 mice examined, includ-
ing the three mice culled showing possible clinical signs of 
disease, showed any TSE-associated spongiform degenera-
tion in the brain regardless of the sequence or conformer of 
recPrP inoculated, or genotype of recipient mouse. 
101LL mice inoculated with recPrP amyloid fibrils 
form PrP amyloid plaques in brain tissue
Brain sections from all 378 mice were analysed for PrP 
deposition by immunostaining with anti-PrP Mab 6H4. 
All mice inoculated with α-monomeric recPrP, oligomeric 
Fig. 1  RecPrP refolded into 
amyloid fibrils was examined 
for fibrillar morphology by EM. 
Phosphotungstic acid-stained 
fibrils from 101L-recPrP (a) 
and WT-recPrP (b). Scale bars 
200 nm
Table 1  Inoculation of 
WT-recPrP and 101L-recPrP 
isoforms
Bold highlights transmissions which resulted in amyloid plaque deposition in 101LL mice
a All primary experiments terminated ~700 dpi. Survival termed as time from inoculation to cull
Inoculum Recipient Survival (±SEM)a Spongiform degeneration PrP amyloid plaques
WT monomer 101LL 586 ± 26 0/21 0/21
129/Ola Wt 518 ± 24 0/21 0/21
101L Monomer 101LL 608 ± 20 0/22 0/22
129/Ola Wt 603 ± 31 0/22 0/22
Monomer control 101LL 558 ± 30 0/19 0/19
129/Ola Wt 653 ± 19 0/21 0/21
WT oligomer 101LL 509 ± 25 0/19 0/19
129/Ola Wt 526 ± 29 0/22 0/22
101L oligomer 101LL 550 ± 18 0/21 0/21
129/Ola Wt 587 ± 20 0/22 0/22
Oligomer control 101LL 543 ± 15 0/24 0/24
129/Ola Wt 559 ± 23 0/23 0/23
WT amyloid fibril 101LL 508 ± 19 0/21 10/21
129/Ola Wt 605 ± 17 0/20 0/20
101L amyloid fibril 101LL 519 ± 27 0/19 14/19
129/Ola Wt 560 ± 30 0/18 0/18
Amyloid fibril control 101LL 537 ± 25 0/19 0/19
129/Ola Wt 628 ± 15 0/24 0/24
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recPrP or saline control inocula were negative for any 
forms of PrP deposition in brain tissue by immunohisto-
chemistry (IHC) and showed no thioflavin-s fluorescence 
regardless of sequence of recPrP or recipient mouse gen-
otype (Figs. 2, 3). Hence, preparations containing only 
monomeric and oligomeric isoforms, generated under our 
experimental conditions, were unable to elicit neurological 
disease, spongiform degeneration, or induce PrP aggrega-
tion in wild-type or 101LL mice. However, some 101LL 
mice inoculated with either WT-recPrP or 101L-recPrP 
amyloid fibrils showed large thioflavin-s fluorescent PrP 
amyloid plaques that were absent in wild-type mice that 
received the same inocula (Figs. 2, 3). Large multicentric 
plaques were observed in 10/21 101LL mice that received 
WT-recPrP amyloid fibrils, and in 14/19 101LL mice that 
received 101L-recPrP fibrils (Table 1). Plaques were pre-
sent mainly in the corpus callosum and vicinity, as well 
as in some areas of the stratum lacunosum and stratum 
moleculare of the hippocampus. In a few animals, plaques 
were also visible in the subventricular area. Plaque mor-
phology was variable, and composed of unicentric, stel-
late and multicentric deposits. Bilateral distribution of 
plaques (in the corpus callosum, hippocampus and stria-
tum) was observed in animals for which whole brain slices 
were available (Figure S1). Analysis by histoblot showed 
plaques to be formed of proteinase K-resistant PrP (Fig-
ure S2). Gliosis and glial cell activation was similar to that 
observed in aged matched un-inoculated control 101LL 
mice (Fig. 3). No obvious difference in plaque morphol-
ogy or distribution was observed in recipient 101LL mice 
following challenge with either WT-recPrP or 101L-recPrP 
preparation. Overall, despite the absence of TSE disease, 
PrP amyloid plaques were induced in 101LL mice follow-
ing inoculation of recPrP fibrils. 
Plaques formed in vivo by recPrP fibril seeding do not 
cause TSE disease on subpassage
Previous experiments by other researchers have demon-
strated the development and serial transmission of TSE dis-
ease in hamsters and mice following inoculation of “syn-
thetic prions” created from refolded recPrP fibrils [12, 13, 
37, 39, 40, 42, 61]. We observed no clinical signs of TSE 
or spongiform degeneration following primary inoculation 
of mice with the different recPrP conformers described 
here, yet PrP amyloid plaques were observed in some 
101LL mice. Subpassage of tissues from 101LL mice that 
received refolded oligomeric and amyloid recPrP isoforms 
was, therefore, performed to determine whether these tis-
sues harboured low levels of TSE infection and could trans-
mit TSE disease. We prepared inocula from brain tissue of 
two 101LL mice that had received 101L-recPrP oligomers 
(inocula 1 and 2) and two 101LL mice that had received 
either 101L (inoculum 3) or WT-recPrP amyloid fibrils 
(inoculum 4) (Table 2). The two mice that received recPrP 
amyloid fibrils were culled at 520 (inoculum 3) and 516 
(inoculum 4) days post-inoculation, and both had PrP amy-
loid plaques identified in the brain by immunostaining. Two 
corresponding buffer control-inoculated mice (inoculum 5 
produced under amyloid refolding conditions, inoculum 6 
under oligomer refolding conditions) were also selected as 
negative controls (Table 2). The six inocula were injected 
intracerebrally into groups of 24 × 101LL mice and 24 
x wild-type mice, and animals were monitored for clini-
cal signs of TSE disease. Experiments were terminated 
approximately 500 days post-inoculation. Of the 288 mice 
inoculated, 16 died due to intercurrent illness, and no tis-
sues were harvested. Neurological signs suggestive of TSE 
disease were observed in 8 of the remaining 272 mice (4 
Fig. 2  Immunohistochemical analysis of brain sections from 101LL 
or wild-type mice inoculated with oligomeric (a, b, e, f) or fibrillar 
(c, d, g, h) refolded recPrP preparations. Abundant plaque deposition 
was observed only in 101LL mice that received fibrillar preparations 
(g, h), and was most prominent in the corpus callosum and hippocam-
pus. Sections stained with anti-PrP Mab 6H4. Scale bar 200 µm
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Fig. 3  Immunohistochemical analysis of PrP deposition and glial 
activation in 101LL mice inoculated with WT-recPrP fibrils (a, b, 
i, j), α-monomeric recPrP (e, f, m, n), or following subpassage from 
101L-recPrP fibril-inoculated 101LL mice with plaque deposition (c, d, 
k, l). Similar patterns of PrP plaque seeding were observed in 101LL 
mice on primary inoculation (a, b) and subpassage (c, d) of WT-recPrP 
fibrils. Thioflavin-s fluorescence of plaques in 101L-recPrP fibril-inoc-
ulated 101LL mice (o, p). Similar amounts and type of glial reactiv-
ity were seen in age-matched, control un-inoculated 101LL mice (g, 
h) and inoculated 101LL mice (i–n). Stained with anti-PrP Mab 6H4 
(a–f); GFAP (astrocytes) (g, i, k and m); Iba I (microglia) (h, j, l and 
n). Scale bars 100 μm (a, c, e, o, p); 50 μm (b, d, f–n)
Table 2  Subpasage of brain 
from recPrP-inoculated 101LL 
mice
Bold highlights transmissions which resulted in amyloid plaque deposition in 101LL mice
All subpassage experiments terminated ~500 dpi
Inoculum Source (mouse  
line/inocula)
Recipient Spongiform  
degeneration
PrP amyloid 
plaques
1 101LL/101L oligomer 101LL 0/24 0/24
129/Ola WT 0/20 0/20
2 101LL/101L oligomer 101LL 0/23 0/23
129/Ola WT 0/22 0/22
3 101LL/101L amyloid fibril 101LL 0/24 18/24
129/Ola WT 0/22 0/22
4 101LL/WT amyloid fibril 101LL 0/23 17/23
129/Ola WT 0/23 0/23
5 101LL/Amyloid fibril control 101LL 0/23 0/23
129/Ola WT 0/22 0/22
6 101LL/Oligomer control 101LL 0/24 0/24
129/Ola WT 0/22 0/22
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from oligomer subpassage and 4 from amyloid subpassage; 
442–619 days old).
None of the 272 mice available for analysis showed 
any TSE-associated spongiform degeneration in the brain. 
Following immunostaining of brain sections, PrP amyloid 
plaques were observed in 18/24 101LL mice that received 
inoculum 3, and 17/23 101LL mice that received inoculum 
4 (Table 2; Fig. 3). No PrP plaques were observed in any 
wild-type mice that had been inoculated with inocula 3 or 
4, or any mice (101LL and wild-type) inoculated with inoc-
ula 1, 2, 5 or 6. Two of the mice culled showing possible 
clinical signs of TSE (culled at 468 days post inoculation) 
were subsequently shown to have PrP amyloid plaques in 
the brain. However, a further 33 mice from the subpassage 
of the recPrP fibrils (29 of which survived >468 days) also 
showed seeding of PrP amyloid plaques, but had no associ-
ated clinical signs of TSE disease. There was also no sig-
nificant difference between the number of possible clinical 
cases in all 101LL vs wild-type groups (Students t Test, 
p = 0.24) and also no correlation between possible clini-
cal signs and plaques in the 101LL mice (Chi-squared test, 
p = 0.24). These neurological signs were probably due to 
intercurrent illness or age-related issues. The inoculation of 
101LL brain containing recPrP fibril seeded plaques was, 
therefore, unable to cause TSE disease in recipient mice.
Ultrastructural pathology following seeding 
with recPrP fibrils is similar to that seen 
following seeding with P102L and P101L PrP 
brain‑derived fibrils
Electron microscopy (EM) was used to examine the brain 
tissue ultrastructure in four 101LL mice that received WT-
recPrP or 101L-recPrP amyloid fibril inocula, and two 
wild-type mice that received 101L-recPrP fibril inocula. 
Plaques were identified in three of the four 101LL mice, 
but not in wild-type mice. All plaques and other accumu-
lations of PrP were located mainly in the corpus callosum 
and stratum lacunosum of the hippocampus.
Two types of plaques were identified by EM following 
both WT-recPrP and 101L-recPrP amyloid fibril inocula-
tion: large multicentric plaques consisting of a dense cen-
tral core of interweaving bundles of amyloid fibrils with 
smaller amyloid cores adjacent to the main plaque. Also, 
smaller, stellate plaques consisting of radially arranged 
bundles of amyloid fibrils were present (Fig. 4). Surround-
ing mature plaques were many dystrophic neurites contain-
ing large numbers of lysosomes and other electron-dense 
organelles and degenerate myelinated axons. Plaques 
were surrounded by reactive astrocytes and microglia. 
Also, granular PrP labelling seen by light microscopy cor-
responded to diffuse areas of loosely arranged amyloid 
fibrils and non-amyloid cell membrane associated PrP 
accumulations that were detected only by immunogold 
electron microscopy.
Immunogold labelling confirmed localisation of aggre-
gated PrP to amyloid fibrils within plaques, but labelling 
for aggregated PrP extended beyond the amyloid fibrils 
and was present on membranes of cellular processes at the 
extreme periphery of the plaque where no visible amyloid 
fibrils were present (Fig. 4). Where plaques were located in 
the corpus callosum, these labelled cells and cell processes 
belonged to astrocytes or oligodendroglia (Fig. 4), suggest-
ing that these cells are the continuing source of fibrillar PrP 
found in mature white matter plaques of the corpus callo-
sum. Dendritic processes were also labelled around plaques 
located in the hippocampal grey matter.
Numerous foci of glial membrane PrP labelling were 
identified in the absence of plaques. Many of these labelled 
membranes were abnormal: processes were highly irregu-
lar, and many small diameter profiles were present, and 
polyp-like protrusion of glial membranes extended from 
processes. Aggregated PrP immunolabelling was par-
ticularly associated with these small irregular membrane 
microfolds or polyps. In rare instances, accumulation of 
aggregated PrP was seen on membranes lacking any other 
visible membrane changes that could be confirmed by EM.
As described previously, and in contrast with classical 
murine scrapie, no intra-lysosomal PrP accumulation was 
evident in any of the mice with plaques, and abnormal 
membrane pathology associated with infectious TSE dis-
ease (tubulovesicular bodies, spiral membrane invagina-
tions, increased coated pits) was also absent. Overall, the 
ultrastructural pathology was more prominent, but similar 
to that previously described in 101LL mice with plaques 
seeded following inoculation of P102L GSS brain-derived 
fibrils [30].
Discussion
Previous work in our laboratory has demonstrated that mis-
folding and aggregation of PrP can occur in the absence 
of TSE agent replication and infectious TSE disease [30, 
55, 56]. These experiments involved inoculation of brain 
material derived from cases of neurological disease (GSS 
patients and sick GSS22 mice overexpressing 101L-PrP), 
which contained other tissue components in addition to 
amyloid protein seeds. Using refolded WT-recPrP and 
101L-recPrP fibrils as inocula, we have now demonstrated 
seeding of PrP amyloid plaques in 101LL mice (but not 
wild type mice), proving that the misfolded protein seed 
alone can initiate plaque formation. No such seeding 
was produced following inoculation of recPrP oligom-
ers or control α-helical PrP isoforms, indicating that amy-
loid fibrils, or specific, smaller protofibrils are required to 
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initiate seeding. Aggregation of 101L-PrP in the host was 
also seeded using both WT-recPrP and 101L-recPrP fibrils 
as inoculum, indicating that it is the structure of the inocu-
lated seed, not the amino acid sequence, that is important 
in initiating aggregation. Hence, both the macromolecu-
lar structure of PrP in the inoculum and the expression of 
mutant 101L-PrP in the host are required for efficient amy-
loid plaque formation. Whether seeding would have been 
observed in wild-type mice if lifespan had been extended is 
unknown, but possible. The 101L mutation in murine PrP 
may alter the kinetics of aggregation, or cellular processes 
involved in the clearance of protein aggregates, resulting in 
an acceleration of the process. These issues will be exam-
ined in future studies of this model.
The creation of “synthetic prions” has been described previ-
ously by others following inoculation of amyloid fibrils derived 
from refolded recPrP sources [12, 13, 37, 39, 40, 42, 43, 61, 66]. 
In contrast to our study, these preparations were shown to cause a 
Fig. 4  Brain tissue from 101LL 
mice inoculated with WT-
recPrP or 101L-recPrP fibrils 
was processed for immunogold 
EM analysis. Immunogold 
labelling of PrP showed small 
and large stellate plaques (a, b) 
with intense labelling of densely 
packed cores (which was not 
evident from light micros-
copy studies). Arrows indicate 
individual amyloid fibrils. 
Membrane immunogold label-
ling was evident in the absence 
of amyloid fibrils adjacent to 
plaques (c circled) and also 
occurred in neuropil uncon-
nected to plaque deposits (d, e) 
where it was mainly located to 
(d) oligodendrocyte membranes 
(ol), (e) astrocytes (as), and 
occasionally to microglia (m). 
Scale bars 500 nm (a), 2 µm 
(b–d), 1 µm (e)
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neurological disease/TSE on primary inoculation or subpassage 
in mice. One recent study has also shown development of neuro-
logical disease following inoculation of recPrP oligomers rather 
than fibrils, but only following refolding in the presence of RNA 
molecules extracted from purified 263K scrapie fibrils [66]. It is 
difficult to draw general conclusions from these experiments as 
in each case, the conditions used to refold recPrP prior to inocu-
lation were different, with varying concentrations of denaturant, 
different buffering, and variations in speed of agitation [12, 37, 
39, 42, 61, 66]. Inoculations were performed in different mouse 
lines [12, 13, 37, 61], and hamsters [39, 40, 42, 43, 66], using 
amounts of recPrP ranging from 0.2 µg [66] to 30 µg [12]. Fol-
lowing recPrP fibril inoculation, some studies [39, 40, 42, 61] 
did show evidence of PrP aggregation in brain in the absence of 
TSE disease, agreeing with the data presented here. However, in 
contrast to our study where only plaque formation was observed 
on subpassage, neurological disease/TSE was observed in mice 
following subpassage of these other models [39–41, 61]. A 
recent study which examined 19,468 unique refolding conditions 
and assayed by infection in cell culture concluded that none of 
the conditions reproducibly created high-titre infectious synthetic 
prions, and that creation of synthetic infectivity is a rare event 
which cannot be efficiently reproduced in vitro [64].
EM analysis of subpassage tissue from 101LL mice with 
seeded plaques confirmed that amyloid plaques (including 
multicentric plaques) seeded by recPrP shared the same origin 
on cell membranes, the same growth by conversion of native 
cell-membrane PrPC on cellular processes and seed dispersal 
through the interstitial spaces as those previously described 
in 101LL mice inoculated with atypical GSS [30]. Similarly, 
101LL mice showed no abnormal membrane pathology and 
intra-lysosomal PrP labelling, both associated with TSE dis-
ease [30, 31]. The generation of abnormal PrP predominantly 
by oligodendroglial cells is also atypical of that of classical, 
naturally occurring TSEs, where most abnormal PrP is formed 
on the surface of neuronal dendrites. These data suggest that 
recPrP fibrils and GSS inocula seed plaque formation by a 
common mechanism, and that plaques in GSS-inoculated 
101LL mice were formed from amyloid seeds in the atypical 
GSS inoculum, and not from other components of the inocu-
lum. Although no TSE disease was observed in atypical GSS-
inoculated 101LL mice, it should be noted that these isolates 
do appear to be transmissible in different animal models [58]. 
Interestingly, the lack of abnormal membrane pathology and 
intra-lysosomal PrP staining was also observed following path-
ological analysis of hamsters with SSLOW (Synthetic Strain 
Leading to Overweight) initiated with refolded recPrP fibrils 
[39–41]. In addition, the localisation of plaques in SSLOW 
hamsters was also distinct from most TSE disease models, 
being found predominantly in the glial limitans and micro-
folded astrocytic processes. The pattern of deposition of amy-
loid plaques in SSLOW hamsters and recPrP fibril-inoculated 
101LL mice may, therefore, be due to distribution of amyloid 
seeds through the extracellular space following high-volume 
intracerebral inoculation. Indeed, distribution of plaques in 
101LL mice mimics the distribution of India ink observed by 
others when inoculated into murine brain [71]. Other stud-
ies have shown that following injection into the brain, inocula 
are drained via perivascular pathways or leak into the CSF and 
enter the blood [72]. Once in the blood, seeds may re-enter the 
brain through the circumventricular organs (CVOs) due to the 
incomplete blood brain barrier at this site [67, 68]. The varia-
tion in pattern and intensity of plaque deposition between dif-
ferent recPrP preparations could, therefore, be determined by 
the aggregate size (due to variations in the refolding conditions) 
and ability to spread via the CSF, interstitial fluid or blood giv-
ing rise to deposition in further areas of the brain via the CVOs.
Our observations of plaque formation in 101LL mice in 
the absence of TSE disease show similarities to work per-
formed, by others, in transgenic mice expressing human 
amyloid precursor protein (huAPP). Plaques can be induced 
in transgenic mice expressing wild-type huAPP and huAPP 
with familial AD mutations following inoculation with AD 
brain homogenate or aged huAPP Tg brain homogenate [47, 
49, 71]. Initial attempts to induce seeding in AD Tgs using 
recombinant Aβ were unsuccessful [47]. However, recent 
studies have demonstrated accelerated seeding in APP23 
mice expressing a GFAP-luc transgene using high levels 
(7.5 μg) of aggregated recombinant Aβ 1–40 monomers 
or mutant Aβ 1–40 dimers (AβS26C)2 [69, 70]. Seeding of 
Aβ plaques may, therefore, occur via a mechanism similar 
to seeding of non-pathogenic PrP amyloid plaques in 101LL 
mice. Recent studies examining archival material from cases 
of iatrogenic CJD (iCJD) have also shown the probable seed-
ing of Aβ plaques in humans following the administration of 
human pituitary-derived growth hormone [29] or the implan-
tation of dura matter grafts [21, 35]. Whilst these materi-
als appear to be the source of Aβ seeds, and responsible 
for the formation of Aβ plaques in brains of the recipients, 
other signs of AD pathology were not present. In particular, 
in the detailed pathological analysis of two cases of iCJD 
that developed following dura matter grafting described by 
Kovacs et al. [35], the authors state that Aβ seeding is unable 
to reproduce the full clinicopathological phenotype of AD.
We have shown that PrP amyloid can be seeded in the brains 
of 101LL mice in the absence of neurological signs of TSE 
disease, spongiform degeneration of the brain and TSE infec-
tious agent replication. Importantly, we have established that 
such seeding can occur not only following inoculation of brain 
extracts from human (atypical P102L GSS) and murine (GSS-
22) sources, but also from non-brain-derived recPrP fibrils. 
Our data provide no evidence for the generation of “infectious 
prions” following inoculation and subpassage of synthetic PrP 
amyloid fibrils; instead, we observe the induction and main-
tenance of a seeded proteinopathy [30, 55, 56]. The develop-
ment of neurological disease in some synthetic prion models 
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may, therefore, depend on the severity and distribution of PrP 
aggregates in the brain, due to the concentration, volume and 
distribution of seeds inoculated. Indeed, GSS22 Tg mice, which 
overexpress 101L PrP ~12-fold, develop neurological signs, 
spongiform degeneration and PrP amyloid plaques, but do not 
transmit TSE disease on subpassage [53]. Material from the 
brains of these mice can seed plaques in low-expressing (~2-
fold) 101L Tg mice and knock-in 101LL mice [53, 55], indi-
cating that high levels of plaque deposition may, indeed, lead to 
neurological signs, but not to an infectious TSE disease. These 
data have led us to hypothesise that there are three potential 
pathways associated with protein aggregation in the CNS; (a) 
resulting in an infectious TSE disease and replication of the 
TSE infectious agent; (b) the induction of a proteinopathy in 
which large accumulations of amyloid lead to toxic effects in 
the brain, but are not infectious; (c) the seeding of protein accu-
mulations in the brain that are neither infectious nor toxic (as 
determined by absence of neurological signs and spongiform 
degeneration of the brain). On this basis, protein misfolding and 
aggregation in the brain does not invariably lead to replication 
of an “infectious prion”, even when the protein in question is 
PrP. This may explain why some prion diseases (particularly in 
humans) appear to be non-transmissible, such as atypical P102L 
GSS, A117V GSS and P105L GSS [34, 56] (P105L GSS: 
Barron, unpublished data). However, transmission of atypical 
P102L GSS has recently been demonstrated in bank voles [58] 
indicating that transmission of such cases may be possible in 
the right host species. Overall, our results and those of others 
where plaque formation is seeded by inoculation of pre-formed 
protein fibrils (or propagons [16]) are consistent with a seeded 
proteinopathy, in which native proteins can be converted into 
misfolded aggregates, but does not result in a contagious, natu-
rally transmissible neurodegenerative disease. Hence, it may be 
preferable to refer to the formation of misfolded protein aggre-
gates in APP transgenic mice and 101LL mice as “seeded pro-
teinopathy”, rather than “prion-like transmission”, to distinguish 
this mechanism from a truly infectious TSE disease which is 
transmissible from one individual to another.
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